Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as MIRUM. It is marketed under 1 brand name, including LIVMARLI. Available in 6 different strengths, such as EQ 9.5MG BASE/ML, EQ 19MG BASE/ML, EQ 10MG BASE and others, and administered through 2 routes including SOLUTION;ORAL, TABLET;ORAL.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"112528","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"17844a282a634b2391a7","publication_number":"US11260053B2","cleaned_patent_number":"11260053","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-05-26","publication_date":"2022-03-01","legal_status":"Granted"} | US11260053B2 | 01 Mar, 2022 | Granted | 26 May, 2031 | |
{"application_id":"76539","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"0c46e398366b49be9b79","publication_number":"US11229661B2","cleaned_patent_number":"11229661","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-10-26","publication_date":"2022-01-25","legal_status":"Granted"} | US11229661B2 | 25 Jan, 2022 | Granted | 26 Oct, 2032 | |
{"application_id":"112525","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"fb88aeeb9bdb42f7be06","publication_number":"US10512657B2","cleaned_patent_number":"10512657","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-10-26","publication_date":"2019-12-24","legal_status":"Granted"} | US10512657B2 | 24 Dec, 2019 | Granted | 26 Oct, 2032 | |
{"application_id":"112529","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"fb88aeeb9bdb42f7be06","publication_number":"US11376251B2","cleaned_patent_number":"11376251","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-10-26","publication_date":"2022-07-05","legal_status":"Granted"} | US11376251B2 | 05 Jul, 2022 | Granted | 26 Oct, 2032 | |
{"application_id":"112527","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"50d35c748b3a4f3a908d","publication_number":"US11497745B2","cleaned_patent_number":"11497745","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-02-12","publication_date":"2022-11-15","legal_status":"Granted"} | US11497745B2 | 15 Nov, 2022 | Granted | 12 Feb, 2040 | |
{"application_id":"113083","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"f31739939cde4413b792","publication_number":"US11918578B2","cleaned_patent_number":"11918578","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-02-12","publication_date":"2024-03-05","legal_status":"Granted"} | US11918578B2 | 05 Mar, 2024 | Granted | 12 Feb, 2040 | |
{"application_id":"112526","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"50d35c748b3a4f3a908d","publication_number":"US11229647B2","cleaned_patent_number":"11229647","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-02-12","publication_date":"2022-01-25","legal_status":"Granted"} | US11229647B2 | 25 Jan, 2022 | Granted | 12 Feb, 2040 | |
{"application_id":"242159","ingredient":"MARALIXIBAT CHLORIDE","trade_name":"LIVMARLI","family_id":"","publication_number":"US12296050B2","cleaned_patent_number":"12296050","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2043-10-05","publication_date":"2025-05-13","legal_status":"Granted"} | US12296050B2 Formulation | 13 May, 2025 | Granted | 05 Oct, 2043 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Maralixibat Chloride
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.